---
document_datetime: 2025-01-16 12:03:43
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vaxneuvance-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vaxneuvance-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.6432801
conversion_datetime: 2025-12-19 12:13:43.403254
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vaxneuvance

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0029               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 15/01/2025                          |                                             | PL                               |           |
| IB/0027              | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation        | 05/11/2024                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0026             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                          | 13/09/2024   | n/a   |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10975 /202401 | Periodic Safety Update EU Single assessment - pneumococcal polysaccharide conjugate vaccine (15 valent, adsorbed)                                                                                            | 05/09/2024   | n/a   | PRAC Recommendation - maintenance |
| IB/0025             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 03/09/2024   | n/a   |                                   |
| IB/0024             | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                  | 17/07/2024   | n/a   |                                   |
| IB/0023             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                             | 03/07/2024   | n/a   |                                   |
| IB/0022             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                          | 07/06/2024   | n/a   |                                   |
| II/0020             | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                       | 06/06/2024   | n/a   |                                   |
| IB/0019/G           | This was an application for a group of variations. B.II.e.7.a - Change in supplier of packaging                                                                                                              | 16/02/2024   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|                     | components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.e.1.z - Change in immediate packaging of the finished product - Other variation   |            |            |             |                                                                               |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------|
| PSUSA/10975 /202307 | Periodic Safety Update EU Single assessment - pneumococcal polysaccharide conjugate vaccine (15 valent, adsorbed)                                                                                                                                               | 08/02/2024 | n/a        |             | PRAC Recommendation - maintenance                                             |
| IB/0018             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                             | 16/11/2023 | 22/11/2024 | SmPC        |                                                                               |
| PSUSA/10975 /202301 | Periodic Safety Update EU Single assessment - pneumococcal polysaccharide conjugate vaccine (15 valent, adsorbed)                                                                                                                                               | 31/08/2023 | n/a        |             | PRAC Recommendation - maintenance                                             |
| IB/0016             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                          | 14/08/2023 | n/a        |             |                                                                               |
| IB/0014             | B.IV.1.z - Change of a measuring or administration device - Other variation                                                                                                                                                                                     | 28/04/2023 | n/a        |             |                                                                               |
| II/0013/G           | This was an application for a group of variations. Grouped application comprising two type II variations as follows:                                                                                                                                            | 30/03/2023 | 26/04/2023 | SmPC and PL | For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | - To update sections 4.2, 4.4, 4.8, 5.1 of the SmPC in order to add safety data on recipients of haematopoietic stem cell transplant (HSCT) based on final results from study V114-022, listed as a category 3 study in the RMP; This is a Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of Vaxneuvance in Recipients of Allogeneic Hematopoietic Stem Cell Transplant. - To update sections 4.2, 5.1 of the SmPC in order to update the information regarding a 3-dose regimen based on final results from study V114-026; a Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of Vaxneuvance in Healthy Infants. The Package Leaflet is updated accordingly. The RMP version 3.0 (consolidated) has been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to   |            |            |             |                                                                               |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------|
| II/0011 | To update sections 4.2 and 5.1 of the SmPC in order to update the information for immune response after subcutaneous administration based on final results from study V114-P033 (EudraCT: 2019-003644-68), in accordance with Article 46 of the paediatric regulation. V114-P033 is a phase 3 Active- Comparator controlled study to evaluate the Safety,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 30/03/2023 | 26/04/2023 | SmPC and PL | For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                     | Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                          |            |            |                                  |                                                                      |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------|
| PSUSA/10975 /202207 | Periodic Safety Update EU Single assessment - pneumococcal polysaccharide conjugate vaccine (15 valent, adsorbed)                                                                                                                                                                                                                                                                                                                                                                                                                            | 09/02/2023 | n/a        |                                  | PRAC Recommendation - maintenance                                    |
| IB/0012             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                       | 29/11/2022 | n/a        |                                  |                                                                      |
| IA/0010             | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                                                                                                                                                                                   | 03/11/2022 | n/a        |                                  |                                                                      |
| II/0001             | Extension of indication to include treatment of infants, children and adolescents from 6 weeks to less than 18 years of age for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media for Vaxneuvance. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet | 15/09/2022 | 21/10/2022 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion Vaxneuvance-H-C- 5477-II-0001. |

<div style=\"page-break-after: always\"></div>

|                     | and to include editorial changes in the product information. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                      |            |            |      |                                                                                                                                                                     |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0008             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                              | 16/09/2022 | 26/04/2023 | SmPC | Product information was updated to reflect the extension of shelf-life for Vaxneuvance suspension for injection in pre- filled syringe from 24 months to 30 months. |
| II/0007/G           | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes | 01/09/2022 | n/a        |      |                                                                                                                                                                     |
| PSUSA/10975 /202201 | Periodic Safety Update EU Single assessment - pneumococcal polysaccharide conjugate vaccine (15 valent, adsorbed)                                                                                                                                                                                                                                                                                                                                                                                                                | 01/09/2022 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                   |
| IB/0005             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor                                                                                                                                                                                                                                                                                                                                                                                                                                    | 19/07/2022 | n/a        |      |                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         | changes to an approved test procedure                                                                                                                                                                                                        |            |            |                        |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IA/0006 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 01/07/2022 | n/a        |                        |
| IG/1515 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 14/06/2022 | n/a        |                        |
| IB/0003 | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                          | 22/04/2022 | 21/10/2022 | SmPC, Labelling and PL |